Small Prostate BPH Treatment — Why Size Matters

Small-volume BPH — prostates under 40 mL — accounts for roughly 20-30% of all BPH cases. Yet most commercial BPH treatments were designed for the average-to-large prostate, leaving small-prostate patients with a paradox: more options than ever, but few that fit their anatomy.

Why small prostate is a different problem

A small prostate has concentrated, localized obstruction. The lesion is often at the bladder neck or in the apex — not distributed throughout a bulky gland. This anatomical reality changes what treatments can safely and effectively address the obstruction.

It also changes the risk profile. TURP in small prostates carries an elevated rate of bladder neck contracture (BNC) — scar tissue forming at the resection site that re-narrows the outlet weeks to years later. Published rates of post-TURP BNC in small prostates can exceed 10%.

Why most MIST options fall short

Each major commercial MIST brand has a structural reason for limited applicability in small prostates:

• UroLift: Designed for median or lateral lobe obstruction. Small prostates often lack significant lobe protrusion — limiting UroLift's effectiveness.
• Rezūm: Thermal steam ablation. In a small prostate, the safety margin between the treatment zone and the external sphincter narrows — increasing the risk of collateral thermal injury.
• Aquablation: Highly automated waterjet ablation. The $150K+ equipment and $1,800+ per-procedure consumable cost cannot be justified for the smaller tissue volume being treated.
• Optilume: Drug-coated balloon dilation. No published efficacy or safety data specifically for the small-prostate cohort. Paclitaxel long-term safety in this population is unknown.

Why mechanical dilation (TUCBDP) works for small prostate

TUCBDP (Transurethral Columnar Balloon Dilation Procedure) is positioned as a preferred MIST option for small-volume prostates. The reasons map directly to the anatomical realities described above:

• Concentrated lesion → precise dilation: Triple-balloon positioning targets the specific obstruction zone, with controlled expansion across a defined segment.
• No thermal energy: Eliminates the thin-margin thermal injury risk that affects heat-based MIST in small prostates.
• No resection: Avoids creating the resection bed that becomes the substrate for post-TURP bladder neck contracture.
• Low equipment cost: Standard endoscopy is the only prerequisite — making the procedure economically viable for the smaller treatment population.

Clinical evidence

Wang 2020 (TUSP vs TURP) reported a bladder neck contracture rate of 2.0% in the TUCBDP arm vs 15.7% in the TURP arm (P=0.031) — a critical safety differentiator. Long-term follow-up (Huang 2016, FU 38-99 months) showed sustained symptom improvement (IPSS 20.2 → 6.6, a 67% reduction).

For patients with small-volume BPH searching for a treatment that fits their anatomy and protects their long-term outlook, mechanical columnar balloon dilation deserves serious consideration.